대한뉴팜

Amid a severe nationwide influenza outbreak in Korea, Daehan Nupharm has reported a sharp increase in demand for its “Enpiflu Premix Injection,” a one-shot IV treatment for influenza. The number of flu patients visiting medical facilities has skyrocketed to more than ten times the usual levels, with some pharmacies already experiencing shortages of flu treatments and cold medicines.
 

According to the Korea Disease Control and Prevention Agency (KDCA), the number of suspected influenza outpatients during the last week of December 2024 (December 22) reached 73.9 per 1,000, up from 7.3 per 1,000 in early December—a tenfold increase and the highest figure since the major flu outbreak in 2016.
 

Influenza typically presents with sudden high fever (over 38 °C), headache, muscle pain, fatigue, and respiratory symptoms such as cough, sore throat, and sputum production.
If left untreated in the early stages, it can lead to complications including pneumonia, bronchitis, and worsening of chronic conditions.
 

Enpiflu Premix Injection is a peramivir hydrate-based formulation that treats influenza with a single intravenous dose, unlike Tamiflu(oseltamivir), which requires two oral doses per day for five days.
It is approved by the Ministry of Food and Drug Safety for the treatment of influenza A and B infections in adults and children aged two years and older.
Notably, single-dose peramivir therapy demonstrated comparable symptom improvement to Tamiflu in a clinical study involving 1,091 adult patients across 146 medical institutions in Korea, Japan, and Taiwan who received treatment within 48 hours of symptom onset.

Building on the success of its IV treatment portfolio, Daehan Nupharm is set to expand its product lineup with the launch of Arginine Premix Injection in March 2025. Arginine, a semi-essential amino acid and pro-drug of nitric oxide (NO), is often supplemented externally due to its limited natural production in the body.
It is widely known to support metabolic health, vitality, and sexual function.
 

Unlike conventional vial formulations that dominate the domestic arginine injection market, Daehan Nupharm’s Arginine Premix Injection comes in a ready-to-use IV bag, eliminating the need for compounding, preventing potential contamination during mixing, and enabling safer and more convenient administration.